Heartburn

To honor GERD Awareness Week on Nov. 24 to 30, the International Foundation for Gastrointestinal Disorders launched a campaign theme, “Relief Starts with Awareness,” to boost understanding of symptoms and treatments for the disease.

PHILADELPHIA — On-demand vonoprazan effectively reduced heartburn symptom severity in patients with nonerosive reflux disease within 1 hour of treatment, according to data presented at the ACG Annual Scientific Meeting.

The FDA has expanded approval for Phathom Pharmaceuticals’ Voquezna tablets 10 mg to alleviate heartburn related in non-erosive gastroesophageal reflux disease, according to a company press release.

WASHINGTON — Vonoprazan effectively relieved heartburn symptoms in patients with nonerosive reflux disease as early as day 1 of treatment, with results persisting after a 4-week placebo-controlled period through 20 weeks, according to data.

More than 9% of patients on glucagon-like peptide-1 receptor agonists who underwent esophagogastroduodenoscopy had retained gastric contents, although the risk for aspiration remained low, according to study results.

BOSTON — There are a handful of “novel and important” treatments that primary care providers should be aware of this year, according to a speaker.

The FDA granted 510(k) clearance to Cyted’s EndoSign, a non-endoscopic capsule sponge device intended to gather pan-esophageal samples for early detection of esophageal cancer as well as other conditions, according to a company release.

Researchers reported that on-demand vonoprazan may be a “reasonable alternative” to daily therapy for heartburn, after demonstrating complete and sustained relief of more heartburn episodes than placebo.

A nationwide survey of nearly 89,000 individuals estimated the prevalence of Rome IV irritable bowel syndrome in the U.S. to be 6.1% compared with 4.7% to 5.3% in previous reports, according to a cross-sectional study in Gastroenterology.